StreetInsider.com News Articles

Nyxoah SA (NYXH) PT Lowered to $6 at Cantor Fitzgerald to Reflect Current Trading Levels

Mon, 17 Aug 2026 08:11:12 -0400

Cantor Fitzgerald analyst Sarah James lowered the price target on Nyxoah SA (NASDAQ: NYXH) to $6.00 (from $11.00) while maintaining an Overweight rating.

The analyst commented, "NYXH advanced its U.S. commercialization strategy while upholding best-in-class prior authorization. It activated 89 new accounts in 2Q26 (now 180 high-volume HGNS accounts) and added 55 new surgeons. It remains optimistic in its capacity to capture 10-15% market share over 12 months, which was the threshold that drove it towards breakeven in Germany. Management noted that in some regions it has well exceeded this, capturing up to 40% market share. We are lowering our price

Nyxoah SA (NYXH) PT Lowered to $6 at Cantor Fitzgerald to Reflect Current Trading Levels

Mon, 17 Aug 2026 08:11:12 -0400

Cantor Fitzgerald analyst Sarah James lowered the price target on Nyxoah SA (NASDAQ: NYXH) to $6.00 (from $11.00) while maintaining an Overweight rating.

Form SCHEDULE 13G/A Nyxoah SA Filed by: CVI Investments, Inc.

Fri, 14 Aug 2026 14:45:00 -0400

si-local-file:///var/storage/secattach/20260814/26929156.html

Form SCHEDULE 13G/A Nyxoah SA Filed by: CVI Investments, Inc.

Fri, 14 Aug 2026 14:45:00 -0400

si-local-file:///var/storage/secattach/20260814/26929156.html

Form SCHEDULE 13G/A Nyxoah SA Filed by: CVI Investments, Inc.

Fri, 14 Aug 2026 14:45:00 -0400

si-local-file:///var/storage/secattach/20260814/26929156.html

Nyxoah SA (NYXH) PT Lowered to $4 at Oppenheimer

Thu, 06 Aug 2026 08:37:39 -0400

Oppenheimer analyst Suraj Kalia lowered the price target on Nyxoah SA (NASDAQ: NYXH) to $4.00 (from $13.00) while maintaining a Outperform rating.

Nyxoah SA (NYXH) PT Lowered to $6 at Piper Sandler

Thu, 06 Aug 2026 07:13:45 -0400

Piper Sandler analyst Adam Maeder lowered the price target on Nyxoah SA (NASDAQ: NYXH) to $6.00 (from $7.00) while maintaining a Overweight rating.

Nyxoah S.A. (NYXH) Misses Q2 EPS by 13c

Thu, 06 Aug 2026 01:53:12 -0400

Nyxoah S.A. (NASDAQ: NYXH) reported Q2 EPS of (EUR0.58), EUR0.13 worse than the analyst estimate of (EUR0.45). Revenue for the quarter came in at EUR7.67 million versus the consensus estimate of EUR8.8 million.

For earnings history and earnings-related data on Nyxoah S.A. (NYXH) click here.

Form 6-K Nyxoah SA For: Jun 30

Wed, 05 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260805/26874485.html

Form 6-K Nyxoah SA For: Jun 30

Wed, 05 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260805/26874485.html

Form 6-K Nyxoah SA For: Jun 30

Wed, 05 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260805/26874485.html

Form 6-K Nyxoah SA For: Jul 09

Thu, 09 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260709/26753587.html

Form 6-K Nyxoah SA For: Jul 09

Thu, 09 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260709/26753587.html

Form 6-K Nyxoah SA For: Jul 09

Thu, 09 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260709/26753587.html

Nyxoah SA (NYXH) Reiterated at Hold by Stifel: Will Breakeven in '2028 if Not Sooner'

Thu, 09 Jul 2026 07:09:15 -0400

Stifel analyst Jonathan Block reiterated a Hold rating and $3.00 price target on Nyxoah SA (NASDAQ: NYXH).

The analyst commented, "We addressed Nyxoah’s 2Q26 preannouncement last night, so we focus on the (limited) incremental takeaways from the Investor Day. The most helpful color was likely specific to the path for Inspire Medical to obtain a specific HGNS code starting in 2028, rather than any incremental information that would alter our cautious stance on Nyxoah.In short, we view the company’s €150MM breakeven revenue aspiration (for 2028, if not sooner), 80% GM (from 61% LTM), and only measured increases in opex as best

Nyxoah SA (NYXH) Reiterated at Hold by Stifel as More Share Dilution Expected

Wed, 08 Jul 2026 07:38:03 -0400

Stifel analyst Jonathan Block reiterated a Hold rating and $3.00 price target on Nyxoah SA (NASDAQ: NYXH).

The analyst commented, "While 2026 Street estimates most likely remain unchanged following 2Q26 top-line results, they are not moving higher, and Nyxoah’s march toward cash flow breakeven remains at least a couple of years away, in our opinion. Our estimates already appear aggressive (see bullet below), with our 2028E reflecting Genio capturing 40% of the incremental HGNS market. Management is assuming an even steeper ramp.Recall, our May 2026 downgrade made the case that $200MM+ in additional capital will be needed for Nyxoah to reach

Form SCHEDULE 13G/A Nyxoah SA Filed by: RESMED INC

Wed, 01 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260701/26716679.html

Form SCHEDULE 13G/A Nyxoah SA Filed by: RESMED INC

Wed, 01 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260701/26716679.html

Form SCHEDULE 13G/A Nyxoah SA Filed by: RESMED INC

Wed, 01 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260701/26716679.html

Form 6-K Nyxoah SA For: Jun 23

Tue, 23 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260623/26679461.html

Form 6-K Nyxoah SA For: Jun 23

Tue, 23 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260623/26679461.html

Form 6-K Nyxoah SA For: Jun 23

Tue, 23 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260623/26679461.html

Form SCHEDULE 13G Nyxoah SA Filed by: HIRSCHMAN ORIN

Mon, 22 Jun 2026 06:17:00 -0400

si-local-file:///var/storage/secattach/20260622/26669471.html

Form SCHEDULE 13G Nyxoah SA Filed by: HIRSCHMAN ORIN

Mon, 22 Jun 2026 06:17:00 -0400

si-local-file:///var/storage/secattach/20260622/26669471.html

Form SCHEDULE 13G Nyxoah SA Filed by: HIRSCHMAN ORIN

Mon, 22 Jun 2026 06:17:00 -0400

si-local-file:///var/storage/secattach/20260622/26669471.html